首页NBIX • NASDAQ
add
Neurocrine Biosciences, Inc.
昨日收盘价
$125.00
当日价格范围
$124.38 - $127.00
年度波幅
$110.52 - $157.98
市值
127.22亿 USD
平均交易量
99.78万
市盈率
33.65
股息率
-
主要交易所
NASDAQ
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 6.22亿 | 24.72% |
经营支出 | 2.34亿 | 14.74% |
净收入 | 1.30亿 | 56.20% |
净利润率 | 20.86 | 25.21% |
每股收益 | 1.81 | 17.53% |
息税折旧摊销前利润 | 1.91亿 | 30.40% |
有效税率 | 31.79% | — |
资产负债表
总资产
负债总额
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 12.28亿 | 12.14% |
总资产 | 35.35亿 | 24.11% |
负债总额 | 8.16亿 | -3.55% |
权益总额 | 27.19亿 | — |
发行在外的股份 | 1.01亿 | — |
市净率 | 4.65 | — |
资产回报率 | 13.51% | — |
资本回报率 | 15.91% | — |
现金流
现金净变动
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | 1.30亿 | 56.20% |
来自运营的现金 | 1.58亿 | -25.47% |
投资现金 | 2470.00万 | 125.39% |
融资现金 | 2640.00万 | 40.43% |
现金净变动 | 2.09亿 | 56.85% |
自由现金流 | -1040.00万 | -106.50% |
简介
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
CEO
成立时间
1992
员工数量
1,700
